CA1039632A - Substrate for immunological tests and method of fabrication thereof - Google Patents

Substrate for immunological tests and method of fabrication thereof

Info

Publication number
CA1039632A
CA1039632A CA218,333A CA218333A CA1039632A CA 1039632 A CA1039632 A CA 1039632A CA 218333 A CA218333 A CA 218333A CA 1039632 A CA1039632 A CA 1039632A
Authority
CA
Canada
Prior art keywords
coating
set forth
device set
substrate
indium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA218,333A
Other languages
French (fr)
Other versions
CA218333S (en
Inventor
Ivar Giaever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Electric Co
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Electric Co filed Critical General Electric Co
Application granted granted Critical
Publication of CA1039632A publication Critical patent/CA1039632A/en
Expired legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553Metal or metal coated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/805Optical property
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809Multifield plates or multicontainer arrays
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/82Hepatitis associated antigens and antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/26Web or sheet containing structurally defined element or component, the element or component having a specified physical dimension
    • Y10T428/263Coating layer not in excess of 5 mils thick or equivalent
    • Y10T428/264Up to 3 mils
    • Y10T428/2651 mil or less
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • Y10T428/31725Of polyamide
    • Y10T428/31768Natural source-type polyamide [e.g., casein, gelatin, etc.]

Abstract

IMPROVED SUBSTRATE FOR IMMUNOLOGICAL TESTS
AND METHOD OF FABRICATION THEREOF

Abstract of the Disclosure Substrates for providing improved contrast, visible to the unaided eye, between single and double layers of immunologically reactive biological particles are fabricated by depositing an alloy of indium and gold on glass slides, and then heating the slides in air at different temperatures or time intervals to cause various degrees of oxidation of the indium. The various degrees of oxidation produce different colored slides having different sensitivities for different thicknesses of the layers of the biological particles, and each differently colored slide is differently sensitive to single and double layers of particular biological particles.

Description

- ~039632 IMPROVED SUBSTRATE FOR IMMUNOLOGICAL TESTS
AND METHOD OF FABRICATION THEREOF

My invention relates to an improved substrate utilized for detecting an immunological reaction between a first biological particle and a second biological particle specific to the first, and the method of fabrication thereof, and in particular, to a substrate which provides improved contrast, visible to the unaided eye, between mono and biomolecular layers of the immunologically reactive biological particles on the surface of the substrate.
This application is related to my Canadian applications S.N. 172,639 entitled "Method and Apparatus for Detection and Purification of Proteins and Antibodies", filed May 29, 1973 and S.N. 204,262 entitled "Improved Method and Apparatus for Detection and Purification of Proteins and Antibodies" filed July 8, 1974 and assigned as herein. Other publications related to the present invention are "Optical Measurement of the Thickness of a Film Adsorbed From a Solution".
authors I. Langmur et al, Journal of the American Chemical ~-Society, volume 59 (July-December-l937) page 1406, "Immunologic and Enzymatic Reactions Carried Out at a Solid-Liquid Interface" by A. Rothen, Physiological Chemistry and Physics, Volume 5, (1973) Pages 243-258 and "Interactions Among Human Blood Proteins at Interfaces", L. Vroman et al, Federation Proceedings, volume 30, No. 5 (September-October, 1971) pages 1494-1502.
Immunological reactions are highly specific biochemical reactions in which a first immunologically reactive biological - 1 - :

particle (generally a protein) known as the antigen combines (links) with a second protein specific to the antigen, and known as the antibody, to form an immunologically complexed protein. Immunological reactions taking place within a biological system, such as an animal or human being, are vital in combatting disease. In a biological system, the entry of a foreign protein, i.e., the antigen, causes the biological system to produce the specific antibody proteins to the antigen ;
in a process not fully understood at this time. The antibody protein molecules have ~vailable chemical combining or binding sites which complement those of the antigen molecule so that the antigen and antibody chemically link or bond to form an --immunologically complexed protein.
Most antigens are proteins or contain proteins as am ~ ;~
essential part, whereas all antibodies are proteins. Proteins are large molecules of high molecular weight, i.e., are polymers consisting of chains of variable numbers of amino acids. The above-cited co-pending applications disclose that an arbitrary protein will adhere to a substrate in a monomolecular layer only, and that no other arbitrary protein will adhere to the protein layer. On the other hand, the specifically reacting protein to the first protein adsorbed onto the substrate will immunologically bond thereto. In accordance with the teachings of those applications, this discovery is exploited to provide medical diagnostic apparatus in which a slide having a monomolecular layer of one protein adsorbed thereon is used to~test suspected solutions for the presence of the specifically reacting protein thereto. If the specifically reacting protein is present in the solution, the slide after exposure to the solution has a bimolecular ;- ' " ''
-2-protein layer thereon. If the specifically reacting protein be absent from the solution, the slide after exposure to the solution has only the original monomolecular protein thereon. Optical, electrical and chemical means for distinguishing between bimolecular and monomolecular biological particle layers are taught in the related co-pending applications and have different degrees of sensitivity and economy.
Because antibodies are produced by biological systems ~-~
in response to invasions thereof by foreign proteins, the detection of antibod~es in a biological system is of medical diagnostic value in determining the antigens ~o which the system has been exposed. A typical example of diagnostic detection of antibodies is the detection of antibodies to syphilis or ~ -gonorrhea in human serum. Conversely, the detection of certain antigens in a biological system also has medical diagnostic value; examples of diagnostic detection of antigens include detection of HCG-protein molecules in urine as a test for pregnancy, and detection of hepatitis~associated-antigen (HAA) molecules in the blood of prospective blooddonors.
In order to perform such diagnostic tests, the appropriate protein of the immunologically reacting pair must be obtained. The only known source of an antibody protein is a living biological system. More particularly, only vertebrates are known at this time to exhibit immunological reactions to the introduction of a foreign protein. For example, many antibodies are found in the blood serum of animals and human beings which have been `~
exposed to the corresponding antigens. Many antigens, ~

RD-6,38 however, may be controllably produced in laboratory cultures. How~ever, some antigenQ, for example, hepatitis-associated-antigens, are at present, like antibodies~ only obtainable from the higher living biological systems.
S It is known in the immunological art that antibody molecules function as antigens when introduced into the system of a vertebrate to whom they are foreign proteins.
Accordingly, specifically reacting antibodies to a given --antibody may be readily produced in such vertebrate system.
Although the substrates (slides) described in the hereinabove referen~ed patent applications are satisfactory in their performance with many of the immunologically reactive biological particles, for certain diseases such as hepatitis, my previous slides have not provided the desired high degree of contrast between single and double layers of the hepatitis (antigen and antibody) molecules.
Therefore, a principal object of my invention is to provide a simple and improved device for detecting immunological reactions occurring at a solid surface by direct visual observation.
Another object of my invention is to provide an improved substrate which obtains improved contrast between single and double layers of immunologically reactive ~i biological particles.
A further object of my invention is to provide a relatively si~ple method for fabricating the improved `
substrate.
Briefly, and in accordance with the objects of my ;
invention, I fabricate my improved slide by evaporating small globules of indium on the surface of`a suitable substrate ,: ' ' ' , ~ , .
.

RD-67~8 which may conveniently be a glass slide. Alternatively, the indium may be evaporated onto the ~urface of the slide as a thick film of constant thickness. Subsequently, a thin film of gold is evaporated over the indium and some alloying of the indium and gold occurs in this step. Finally, the coated slide is heated in air sufficiently to complete the alloying and to obtain some oxidation of the indium and thereby form an indium oxide film on the outer surface of the substrate coating. The degree of oxidation of the indium determines the color of such oxide film which is significantly differently sensitive to single and double layers of particular immunologically reactive biological particles being detected such that the contrast is readily visible to the unaided eye.
The features of my invention which I desire to protect herein are pointed out with particularity in the appended claims.
The invention itself, however, both as to its organization and method of operation together with further objects and advantages thereof, may best be understood by reference to the following description taken in connection with the accompanying drawing wherein:
FIGURE lA is an elevation view of an intermediate structure of the preferred embodiment of my improved substrate;
FIGURE lB i8 an elevation view of the preferred substrate after final fabrication; and FIGURE 2 is an elevation view of a second embodiment of my improved substrate.
Referring now to FIGURE la, there is shown an elevation view of a substrate 10 having a substantially flat top surface and being fabricated of a suitable material which may be a metal, glass, plastic or similar material. Substrate 10 is preferably ~3963Z
in the form of a glass slide such as a conventional microscope cover glass 25 millimeters square and 10 mils thick, the glass slide being preferred primarily due to its low cost and ready commercial availability. After selection of the substrate, the top surface thereof is coated with a plurality of metal globules 11 by evaporating a metal, for example, indium, onto the substrate. Typically, the indium is evaporated slowly from a tantalum boat in the evaporator onto the glass substrate in an ordinary vacuum of about 5 x 10 5 mm of mercury. Because the indium atoms have high mobility on the surface of the substrate and do not wet the glass substrate significantly, the indium evaporated onto the glass slide agglomerates into small -unequal size particles. Some other metals, such as tin, having similar characteristics so that they will also form globules on the substrate when evaporated thereon, and are oxidizible, can be used, and the particular metal used is dependent on the particular immunologically reactive biological solution (including its pH) being investigated. The slow evaporation of the indium is necessary in order to obtain the globules, the evaporating process taking approximately 3 to 5 minutes. The indium globules have average diameters on the order of 3000 A and are closély spaced together, having an average maximum spacing of approximately lt2"diameter. A
significantly faster evaporation of the indium (i.e., in the order of 30 seconds) results in a deposit on the substrate of a film of relatively constant thickness, as illustrated in FIGURE 2.
After the indium globules 11 have been evaporated on substrate 10, a thin substantially constant thickness film 12 of gold is evaporated over the indium globules, and , , . . ~

10;~963Z
during this evaporation step some alloying of the indium and gold occurs. Other metals than gold may be utilized, such as cvpper or silver when testing other type body fluids.
However, if the immunological test to be conducted requires the use of human serum, as is often the case, it has been found that such other metals are attacked through some chemical reaction and therefore are unsatisfactory. The gold deposition can be accomplished at a faster rate than the indium deposition step, and again may be accomplished by evaporating the gold from a tantalum boat in an ordinary vacuum of about 5 x 10 5 mm of mercury. The gold film 12 is of thickness in the order of 1000 A for the best contrast between a monomolecular layer of hepatitis B antigen (HBAg) and a bimolecular layer of such antigen and its specific antibody (HBAb) for an indium layer of average thickness of 2000 A. Thus, the average thickness of the indium layer (i.e., a constant thickness layer that would be obtained from globules 11) is approximately twice the thickness of the gold film 12. The intermediate structure of the coated substrate after evaporation of the gold film thereon is similar to that illustrated in FIGURE la with the gold film 12 forming an irregular or uneven undulating pattern (due to the indium globules~ that diffracts incident light, and with the understanding that some alloying of the indium and gold has occurred as described in my referenced application S.N. 204,262. The evaporation of the indium and gold onto the substrate can be accomplished in any suitable evaporator, a typical evaporator being model type CV-18 manufactured by Consolidated Vacuum Corp., Rochester, N.Y. A Deposit Thickness Monitor, model DTM-3 and Deposit Rate Control, model DRC, both manufactured by Sloan :,5.

Instrument Corp., Santa Barbara, California were utilized with the aforementioned evaporator for obtaining the desired thickness and rate of deposition of the indium and gold metals being evaporated. Due to the maximum current limitation in the aforementioned evaporator, the gold could not be evaporated as rapidly as it could be in a higher power evaporator, and such evaporation prOcesstherefore took about 3 minutes.
After the gold has been evaporated on the indium globule-coated substrate, the coated substrate is removed from the evaporator and placed in a suitable electric furnace for heating in an air atmosphere sufficiently to obtain some oxidation of the indium and thereby form an indium oxide film on the outer surface of the substrate coating having the irregular pattern of t~e gold film in FIG. la. This oxidation step also completes the alloying of the indium and gold. The degree of oxidation of the indium determines the color of such oxide film. The various degrees of oxidation produce different colored slides having different sensitivities for different thicknesses of the layers of the biological particles, and each differently colored slide is differently sensitive to single and double layers of particular biological particles. The oxidation accomplished by heating for approximately 150 minutes -at 325& yields an indium oxide film having greenish-gold or bronze color. A lesser degree of oxidation produced by heating 325C for 100 minutes produces a reddish-gold color. A
greater oxidation of the indium produced by heating at 325C for 30-45 minutes produces a blue color. The greenish-gold (bronze) color is presently the preferred color for HAA as will be described hereinafter, and such- oxide film has a thickness 30 in the order of several hundred Angstrom. ~ -In the case of only indium globules evaporated on the substrate, as taught in my hereinabove referenced patent application S.N. 204,262, the detection of a single or double layer of imm~nologically reactive biological particles thereon is obtained by light transmission, that is, the test is accomplished by direct visual observation of the light transmitted through the slide. In the case of my present gold-indium alloy and indium oxide coated substrate, the biological particle layers are detected by reflected light since the irregular surface of the indium oxide diffracts the incident light. The coated substrate, after the indium oxidation process, appears as in FIGURE lB. The 25 millimeter square coated slides may then be cut into approximately 4 equal squares for use in the immunological tests to be described hereinafter. Obviously, a commercial production of my slides would probably begin with a much larger size glass, and could be cut to any desired size slides. The cutting process may utilize conventional glass cutting techniques such as scoring the glass with a diamond scribe, and then breaking the glass along the scored lines.
My finished substrate, as illustrated in FIGURE lB
(or 2) is placed on a suitable support and a monomolecular layer of a first immunologically reactive biological particle is adhered onto the coated surrace of the substrate. The adherence of the first biological particles may be accomplished by depositing a single drop of a first solution of the first biological particle on the substrate coated surface. The first biological particle is selected on the basis of its being specific to particular second biological particles which will form the second layer on the substrate surface if _g _ they are present in a solution to be tested. The first particles may be produced in laboratory cultures or obtained from the higher living biological systems as described hereinabove, and are generally commercially available in highly purified 5 form, and if not available commercially, may be purified chemically. The solution of the first biological particles may be a salt solution of water or other liquid appropriate to, and not reactive with, the first biological particles.
The substrate is preferably stored in a moist chamber for a time interval sufficient so that the first biological particles in the drop of the first solution are adsorbed onto the coated surface of substrate 10 and form a substantially complete monomole~ular layer in the pattern of the drop in accordance with the teachings of the aforementioned Canadian patent applications of Giaever. The time interval (generally up to 1 hour) for the formation of the monomolecular layer on substrate 10 is an inverse function of the concentration of the first particle in the solution. The area size of the monomolecular layer on the substrate coated surface is 20 preferably as small as practicable, and is generally in the -range of 1 square millimeter to 1 square centimeter in order to conserve the amount of biological material used in the process. A rinsing of the coated surface of substrate 10 is often recommended after the fbrmation of the monomolecular layer thereon in order to minimize nonspecific adsorption. The monomolecular layer coated substrate is then dried, if the slide is to be shipped commercially or s~ored, preferably by blowing air at room temperature across the substrate in order -~
to speed the drying process. If the slide is to be used immediately, there is no need to dry it after the rinsing. For '' - ' 1039~3Z
commercial use by others, the metallized slide could be sold by the slide manufacturer with or without the first monomolecular layer thereon. The spot on the substrate coated surface caused by the monomolecular layer pattern is generally barely, if at all, visible to the unaided eye.
The monomolecular layer coated substrate is then exposed to a second solution suspected of containing second immunologically reactive biological particles specific to the first in a direct test for such second particles. This exposure is generally aceomplished by ~mmersing the monomolecular l~yer coflted substrate in the second solution for a time interval which is again an inverse function of the concentration of the second biological particles in the second solution. Since the concentration of the second particles is generally much less than the concentration of the first particle in the first solution, the immersen~
step generally takes much longer than the time interval for for~ing the first monomolecular layer, and may take up to 24 hours. Presence of the second biological particles in the second solution results in the formation of a second substantially complete monomolecular layer on the pattern (generally a round spot) established on the coated substrate by the first monomolecular layer as a result of the immunologica reaction wherein the second particles become bound to the first particles.
After the coated substrate has been sufficiently exposed to the second solution, the substrate is removed therefrom and may be immediately visually examined. Alternatively, and more generally, the substrate after removal from the second solution is ~gain rinsed with a suitable solution which, in many 1039~3Z
cases, may be water or a salt solutlon thereof, and the slide is then dried. The direct visual observation of the coated substrate is made by detecting the reflection off the coated surface of the substrflte due to the light diffraction occurring 5 at the oxidized surfsce, rather than by detecting the light transmitted therethrough. Absence of the second biological particles in the second solution results in only the presence of the monomolecular layer on the coated substrate surface and, as noted hereinabove, such single layer of biological particles is 10 barely, if at all, visible on my improved slides. However, presence of the second particles in the second solution develops the second layer described hereinabove and produces ~
surprisingly different colored spot on the substrate so that the ~ -contrast between single and double layers of immunologically 15 reactive biologic~l particles is very pronounced.
As noted above, the different degrees of oxidation of the indium produce different colored slides, and it has been found that different colored slides have different -sensitivities for different thicknesses of particular 20 biological particle layers. Thus, a particular colored slide is selected for the particular biologic~l particle being investigated since such p~rticular colored slide has the best sensitivity for such biological particle system.
The greenish-gold (bronze) colored slide has been found 25 to have the highest sensitivity for detecting the difference between single and double layers of many types of immunologically reactive biolo~ical pflrticle systems, that is, provides the highest degree of contrast for detecting the double layer which appears as a purplish spot on the slide. Although this particular 30 color of the indium oxide film h~s been described as being 1039~ii3Z
obtained by heating the slide in air for 150 minutes at 325C, it should be obvious that a comparable color ~xide film may be obtained by heating the slide at a higher temperature for a shorter time, or at a lower temperature for a longer time.
FIGURE 2 illustrates a second embodiment of my improved substrate. This embodiment is fabricated in the same manner as the first embodiment except for the first step. In the first step, a thick continuous (as opposed to the noncontinuous ~ film of globules in FIGURE 1~) film of indium of substantially constant thickness is evaporated on the top surface of substrate 10. This thick film, in the order of 3000 A thickness, is obtained by evaporating the indium at a much faster rate than in the case of the first embodiment~ the evaporation interval being approximately 30 seconds. Alternatively, the gold can be evaporated ~n the substrate before the indium. The finished structure of the FIGURE 2 embodiment thus includes substrate 10, a layer 3~ of indium-gold alloy of substantially constant thickness and an indium oxide film 13 which is flat. The light diffraction produced from t~e indium oxide film 13 in the FIGURE 2 embodiment results from gold particles dispersed therein during the oxidation process. Such gold particles contribute to a high dielectric constant and therefore promote very visible interference colors. Such gold particles are probably present in the indium oxide film in FIGURE lb.
A specific application of my improved substrate for the detection of hepatitis B antigen (B Ag) and antibody (HsAb) will now be described. This particular biological system requires a very sensitive test since the HBAg is a large size protein (mo~ecular weight of 5 x 106) whereas the HBAb is small (M.W. of 1.6 x 105) so that the added thickness of an HBAb ; 1~39~3Z RD-6738 monomolecular layer to one of HBag does not produce a l~rge I chflnge in thickness. Experiments involving single and double ; layers of the HBAg and sAb molecules on the anodized tantalum slides described in the hereinabove referenced Rothen article S were not very satisfactory since a Qufficient contrast between the single and double layers for a sensitive test was not obtained. However, the use of my improved substrate described herein provided a high degree of contrast between the single ~nd double layers so thst the layers were detected with at least the same sensitivity as in standard radioimmunoassay tests.
IQ the tests for detecting the hepatitis B antigen and antibody, the first step requires the adsorption of a monomolecular layer of B Ag onto the coated surface of my substrate. Since the HBAg is readily available in purified ~orm, a drop of a common solution thereof (such as a salt solution) is applied onto the coated surface of the slide. The drop of this first solution is maintained on the substrate surface for a time interval sufficient to obtain a substantially complete monomolecular layer over the area of the drop, and may be in the order of 15 to 30 minutes with the slide being stored in a moist chamber to prevent evaporation of the drop. The slide is then rinsed with distilled water and may subsequently be gently -blown dry with compressed air, although this drying step is aot essential. The HBAg has now been adsorbed from the drop of solution in a small monomolecular layer spot on the coated slide surface and is barely, if at all, visible to the unaided eye.
The s Ag monomolecular layered slide is next exposed to a second solution suspected of containing the HsAb. This second solution is generally a human serum sample. The exposure is generally accomplished by immersing the slide in the second 1~3~32 solution for an interval up to about 24 hours due to the con-centration of the specific antibody in the serum sample being low, if at all present. The slide is then again rinsed and dried and visually examined with the naked eye. A purplish spot on the slide indicates presence of a second monomolecuJ.ar layer (i.e., the HBAb layer) whsreas absence of the spot indicates absence of B Ab in the human serum sample in a direct test therefor.
The direct test for HBAg can be accomplished in a similar manner as described above, with HsAb being adsorbed on the coated slide surface as a small spot forming the ~irst monomolecular layer, and H~Ag in the second solution (human serum sample), i~
present, forming the second monomolecular layer.
An indirect or inhibition test for the detection of HBAg may also be demonstrated using my improved slide.
The principle of the inhibition test is that HBAg particles, if present in sufficient quantity~ will neutralize free B Ab in solution. This reaction will prevent the antibodies from forming observable complexes (i.e., a bimolecular layer) when the slide with the antigen spot (first monomolecular layer) is exposed to the solution.
The inhibition test is accomplished as ~ollows:
A monomolecular layer spot on HBAg is adsorbed on the coated slide surface as in the direct test described hereinabove.
he second solution is prepared by adding the human serum sample to be tested to a solution of HBAb in a vial or other suitable container. The vial is then stored for a ti~ interval sufficient for the HBAb to complex with HBAg in the human sample, if the antigen is present therein. The vial is preferably agitated to increase the rate of complexing. Finally, the HBAg monomolecular spot covered slide is immersed in the second solution, and after .. . . -1~3963Z
a suitable period of time (again up to 24 hours), the slide is removed, rinsed, dried and visually examined. The results of this inhibition test are the opposite of the direct test, that is, presence of the HBAg in the human serum sample ~
5 produces no purplish spot on the slide, i.e., produces no - ;
second monomoleclular layer on the slide, whereas presence of ` such purplish spot indicates absence of the HBAg in the ` human serum sample.
The inhibition test for the detection of ~BAb is performed similarly to the inhibition test for HBAg with the obvious substitution of the antigen for antibody and antibody for antigen in each of the steps.
In all of the above tests, the HBAb may be obtained from human serum of a patient k~own to have hepatitis B, or it may be developed in a goat, rabbit or other suitable animal by ;~ injection thereof with the HBAg, waiting a suitable incubation `; period such as two weeks, and then drawing bloJd containing the specific antibody from the animal and separating the antibody from the remaining blood particles.
The same significant visual contrast of a purplish spot against a bronze color background was found for a CEA (cancer embryonic antigen) and anti-CEA double layer and for a BSA
(bovine serum albumin) and anti-BSA double layer as compared to a barely, if at all, visible spot for a single layer of the CEA or BS~ particles. In the case of a blue colored slide, the double layer spot was white.
From the foregoing description, it can be appre~ated that my invention makes available an improved substrate for detecting immunological reactions occurring at the surface thereof by direct visual observation with the unaided eye, ':

' , .
" ' ~

1~:)39632 as well as a method for fabricating the improved substrate.
The improved substrate has a metallized coating including an alloy of two metals and an oxide of one of such metals.
Thus, the two metals can be identified as a base metal and noble metal since only the base metal can be oxidized, and is overcoated by the second (noble) metal. Also, there is no reason to limit the coating to two metals, one of the materials can be of the semiconductor type,and the materials are not necessarily limited to only two, there may be more. In the case of the metallized coating being an indium-gold alloy and indium oxide, such coated substrate provides significantly improved contrast between single and double monomolecular layers of immunologically reactive biological particles including a single layer of hepatitis B antigen and a second single layer of its specific hepatitis B antibody. Different degrees of oxidation of the indium may be found more useful with other types of pairs of immunologically reactive biological particles for increasing .; .
the contrast thereof between single and double layers. The coated substrate of my invention is a simple, relatively inexpen-sive device which is easily fabricated in accordance withanother aspect of my invention. The major advantage of my invention is the significantly improved contrast between single and double layers of immunologically reactive biological particles which thereby permits detection of such immunological reaction by direct observation visible to the unaided eye.
Having described my invention with reference to two particular embodiments, it is believed obvious that modification and variation of my invention is possible in the light of the above teachings. Thus, the coating on the substrate may be formed of an alloy of two mor mo-e metals (or metal and :~.
. -17-.'' ' ' .' . '' :' , , , RD-6738 11)39~3Z
semiconductor other than the indium and gold, with the base metal forming the outer oxidized surface. Such other alloy-oxide coated substrate may be found to obtain better contrast between single and double layers of some immunologically reactive biological particles other than the hepatitis type than if the indium-gold slide was used. That is, each pair of `~ immunologically reactive biological particles are detected with the greatest contrast between single an~d double layers thereof with a specific substrate fabricated in accordance with my invention.
Finally, the irregular surfaced slide constituting my first embodiment could obviously also be fabricated by starting with an irregular surfaced substrate and evaporating constant thickness layers of indium and gold thereon. It is, therefore, to be understood that changes may be made in the particular embodiment of my invention as described which are within the full intended scope of the invention as defined by the following claims.
',,' :
. .

, '''' , , ,, .
., .
`~" '.

;
. , ; :
.

- , . .: , . -: ' . ' ' ' ': ' .

Claims (17)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A medical diagnostic device comprising:
a substrate member, and a composite metallized coating attached to the surface of said substrate member, said coating containing an alloy having a noble metal constituent and an oxidizable metallic constituent, said coating having present in the outer surface thereof oxide content derived from said oxidizable metallic constituent, and said coating being free of oxide of said noble metal constituent.
2. The device set forth in claim 1, wherein the noble metal constituent is gold.
3. The device set forth in claim 1, wherein the oxidizable metallic constituent is indium, the noble metal con-stituent is gold, and the oxide content is of indium oxide.
4. The device set forth in claim 1, wherein the surface of the substrate receiving the coating is flat.
5. The device set forth in claim 1, wherein the substrate is a glass material.
6. The device set forth in claim 1, wherein the oxidizable metallic component is tin.
7. The device set forth in claim 1, wherein the noble metal constituent is silver.
8. The device set forth in claim 1, wherein the oxidizable metallic constituent is indium.
9. The device set forth in claim 8, wherein the color of the coating is bronze.
10. The device set forth in claim 1, wherein the outer surface of the coating is slightly irregular.
11. The device set forth in claim 10, wherein the oxide portion of the coating is about several hundred Angstrom thick.
12. The device set forth in claim 1, wherein the outer surface of the coating is flat.
13. The device set forth in claim 12, wherein unoxidized particles of the noble metal constituent are dis-persed within the oxide portion of the coating.
14. A medical diagnostic device comprising:
a substrate member, a composite metallized coating attached to the surface of said substrate member, said coating containing an alloy having a noble metal constituent and an oxidizable metallic constituent, said coating having present in the outer surface thereof oxide content derived from said oxidizable metallic constituent, and said coating being free of oxide of said noble metal constituent, and a monomolecular layer of immunologically reactive protein over-lying at least a portion of said coating.
15. The device set forth in claim 14, wherein the protein is an antigen.
16. The device set forth in claim 14, wherein the protein is an antibody.
17. The device set forth in claim 14, and further comprising:
a layer of second immunologically reactive protein bound to the first monomolecular layer wherein the second protein is specific to the first protein, the double layer of first and second proteins being visible to the unaided eyes as a spot of color distinct from the color of the outer surface of the coating.
CA218,333A 1974-02-25 1975-01-21 Substrate for immunological tests and method of fabrication thereof Expired CA1039632A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US445204A US3926564A (en) 1974-02-25 1974-02-25 Substrate for immunological tests and method of fabrication thereof

Publications (1)

Publication Number Publication Date
CA1039632A true CA1039632A (en) 1978-10-03

Family

ID=23767988

Family Applications (1)

Application Number Title Priority Date Filing Date
CA218,333A Expired CA1039632A (en) 1974-02-25 1975-01-21 Substrate for immunological tests and method of fabrication thereof

Country Status (2)

Country Link
US (1) US3926564A (en)
CA (1) CA1039632A (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979184A (en) * 1975-05-27 1976-09-07 General Electric Company Diagnostic device for visually detecting presence of biological particles
US4112925A (en) * 1976-04-22 1978-09-12 Corning Glass Works Blood sample container having an anticoagulant coating of polyvinyl pyrrolidone and a salt of ethylene diamine tetracetate
US4090849A (en) * 1976-12-20 1978-05-23 General Electric Company Diagnostic device and manufacture thereof
US4219335A (en) * 1978-09-18 1980-08-26 E. I. Du Pont De Nemours And Company Immunochemical testing using tagged reagents
US4247589A (en) * 1977-12-16 1981-01-27 Greenspan Donald J Decorative oxidation process and article
US4181501A (en) * 1979-03-26 1980-01-01 General Electric Company Method and apparatus for measuring antibody levels
DE3215484A1 (en) * 1982-04-26 1983-11-03 Sagax Instrument AB, 18302 Täby MULTIPLE LAYERS OF LAYER AND PROCESS FOR DETECTING AND / OR MEASURING THE CONCENTRATION OF A CHEMICAL SUBSTANCE, IN PARTICULAR BIOLOGICAL ORIGIN
DE3376685D1 (en) * 1982-12-21 1988-06-23 Ares Serono Nv Assay technique
IL74191A0 (en) * 1984-01-31 1985-04-30 Univ Illinois Method and kit for determining periodontal disease
US5041373A (en) * 1984-01-31 1991-08-20 The Board Of Trustees Of The University Of Illinois Method for determining periodontal disease
US6060237A (en) 1985-02-26 2000-05-09 Biostar, Inc. Devices and methods for optical detection of nucleic acid hybridization
GB8509492D0 (en) * 1985-04-12 1985-05-15 Plessey Co Plc Optical assay
US5482830A (en) * 1986-02-25 1996-01-09 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US4794089A (en) * 1986-03-25 1988-12-27 Midwest Research Microscopy, Inc. Method for electronic detection of a binding reaction
US4727024A (en) * 1986-05-12 1988-02-23 Martin Koocher Binding assays involving formation and detection of light scattering crystals
GB8618133D0 (en) * 1986-07-24 1986-09-03 Pa Consulting Services Biosensors
CA1317206C (en) * 1986-09-22 1993-05-04 Takeyuki Kawaguchi Method for detecting a component of a biological system and detection device and kit therefor
US5089387A (en) * 1988-07-07 1992-02-18 Adeza Biomedical Corporation Dna probe diffraction assay and reagents
CA1337173C (en) * 1989-04-28 1995-10-03 Westaim Biomedical Corp. Thin film diagnostic device
US5639671A (en) * 1989-09-18 1997-06-17 Biostar, Inc. Methods for optimizing of an optical assay device
US5541057A (en) * 1989-09-18 1996-07-30 Biostar, Inc. Methods for detection of an analyte
US5550063A (en) * 1991-02-11 1996-08-27 Biostar, Inc. Methods for production of an optical assay device
US5955377A (en) * 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
US5998220A (en) * 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5877028A (en) * 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
EP0598003B1 (en) * 1991-07-22 1999-02-10 Kloehn Instruments, Ltd. Substrate for surface-enhanced analytical procedures, and substrates prepared for specific procedures
US5837552A (en) * 1991-07-22 1998-11-17 Medifor, Ltd. Surface-enhanced analytical procedures and substrates
US5418136A (en) * 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
US5494829A (en) * 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5552272A (en) * 1993-06-10 1996-09-03 Biostar, Inc. Detection of an analyte by fluorescence using a thin film optical device
US5413939A (en) * 1993-06-29 1995-05-09 First Medical, Inc. Solid-phase binding assay system for interferometrically measuring analytes bound to an active receptor
US5736343A (en) * 1995-08-18 1998-04-07 Landry; Donald Detection of organic compounds through regulation of antibody-catalyzed reactions
DE19601488C1 (en) 1996-01-17 1997-05-28 Itt Ind Gmbh Deutsche Measuring device manufacturing method for measuring or testing physiological parameter at biocomponent
US5679579A (en) * 1996-01-29 1997-10-21 First Medical, Inc. Immunofluorescence measurement of analytes bound to a substrate and apparatus therefor
US5958704A (en) 1997-03-12 1999-09-28 Ddx, Inc. Sensing system for specific substance and molecule detection
DE19753848A1 (en) 1997-12-04 1999-06-10 Roche Diagnostics Gmbh Modification of surfaces to increase surface tension
US6376619B1 (en) * 1998-04-13 2002-04-23 3M Innovative Properties Company High density, miniaturized arrays and methods of manufacturing same
US6395483B1 (en) 1999-09-02 2002-05-28 3M Innovative Properties Company Arrays with mask layers
US7167615B1 (en) 1999-11-05 2007-01-23 Board Of Regents, The University Of Texas System Resonant waveguide-grating filters and sensors and methods for making and using same
US6482638B1 (en) 1999-12-09 2002-11-19 3M Innovative Properties Company Heat-relaxable substrates and arrays
US6492133B1 (en) 2000-05-01 2002-12-10 3M Innovative Properties Company Reflective disc assay devices, systems and methods
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
AU2004273783A1 (en) 2003-07-12 2005-03-31 Accelr8 Technology Corporation Sensitive and rapid biodetection
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
ES2551922T3 (en) 2011-03-07 2015-11-24 Accelerate Diagnostics, Inc. Rapid cell purification systems
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
KR20170132856A (en) 2015-03-30 2017-12-04 액셀러레이트 다이어그노스틱스, 아이엔씨. Instruments and systems for rapid microbiological identification and antimicrobial susceptibility testing
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271179A (en) * 1962-09-24 1966-09-06 Temescal Metallurgical Corp Method for the manufacture of an optical filter
US3530055A (en) * 1968-08-26 1970-09-22 Ibm Formation of layers of solids on substrates
US3694337A (en) * 1971-01-04 1972-09-26 Nippon Sheet Glass Co Ltd Sputtering method for manufacturing transparent,heat ray reflecting glass
US3691045A (en) * 1971-03-15 1972-09-12 Corning Glass Works Method of making photochromic films on glass substrates
US3717563A (en) * 1971-06-09 1973-02-20 Ibm Method of adhering gold to an insulating layer on a semiconductor substrate

Also Published As

Publication number Publication date
US3926564A (en) 1975-12-16

Similar Documents

Publication Publication Date Title
CA1039632A (en) Substrate for immunological tests and method of fabrication thereof
US3960490A (en) Method and apparatus for detecting immunologic reactions by diffusion in gel
US4054646A (en) Method and apparatus for detection of antibodies and antigens
US3979509A (en) Opaque layer method for detecting biological particles
CA1039649A (en) Method of forming multilayer immunologically complexed films
US3960488A (en) Method and apparatus for quantitative surface inhibition test
US3979184A (en) Diagnostic device for visually detecting presence of biological particles
EP0598003B1 (en) Substrate for surface-enhanced analytical procedures, and substrates prepared for specific procedures
US4172827A (en) Method for concentration and purification of antigens and antibodies
US5837552A (en) Surface-enhanced analytical procedures and substrates
JP2528134B2 (en) Method for treating the surface of an optical structure
US4794089A (en) Method for electronic detection of a binding reaction
JPH0224548A (en) Electric detection of immunological reaction
JPH04501605A (en) Detection surfaces capable of selective biomolecular interactions for use in biosensor systems
JP2001503862A (en) Method and apparatus for mass transport assisted optical assay
US4791069A (en) Methods for attaching ligands or anti-ligands to a solid phase
JPH06500391A (en) Analysis equipment
CA1047918A (en) Method and apparatus for detection and purification of proteins and antibodies
JPS5916669B2 (en) Antigen or antibody detection method
WO1993025910A1 (en) Assay for multiple analytes with co-immobilized ligands
CA1049401A (en) Method and apparatus for detecting immunologic reactions by diffusion in gel
CA1049398A (en) Method and apparatus for detecting immunological reactive biological particles
CA1048409A (en) Method for improving contrast in surface immunological tests with large size proteins
GB1564333A (en) Method for contrast in surface immunological tests
GB1562804A (en) Detection of antibodies and antigens